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ABSTRACT
Clindamycin is one of the important alternative antibiotics in 
the therapy of Staphylococcus aureus infections. The limited 
treatment options for MRSA, increaes the importance of the 
right antibiotic.The major problem of the use of clindamycin 
for such infections is the presence of inducible clindamycin 
resistance that can lead to treatment failure. The aim of this 
study was to investigate the inducible clindamycin resistance 
of 86 MRSA strains isolated from Research Hospital of Ataturk 
University. Inducible clindamiycin resistance was detected 
using D zone test method according to Clinical and Laboratory 
Standards Institute (CLSI) instructions. Twenty of the strains 
exhibited the iMLSB, 8 exhibited the cMLSB and 22 exhibited 
the MS phenotype. The D zone test, which can be done by using 
erythromycin and clindamycin discs, is a simple disc diffusion 
test for detection MLSB phenotype and clinical laboratories 
should report in vitro inducible clindamycin resistance in all S. 
aureus isolates.
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INTRODUCTION
Staphylococci, which is a member of the normal flora on the 
skin can cause various infections as opportunistic pathogens 
(1). Nosocomial and community acquired methicillin-
resistant Staphylococcus aureus (MRSA) infections are 
common worldwide (2). The microorganism is responsible 
for many infections such as skin, soft tissue, eye, ear, 
bone infections and illness like pneumonia, endocarditis, 
meningitis and septicaemia (3). Today, perevalance of MRSA 
varies according to countries, regions and also to the hospitals 
and services in the same hospital (4). Although, there are 
many options for control and treatment of staphylococcal 
infections, the choice of the appropriate antibiotic is 
important (5).
Macrolide-lincosamide-streptogramin B (MLSB) antibiotics, 
although chemically different structures have shown similar 
effects on bacterial protein synthesis. Therefore resistance 
genes, causing resistance to MLSB antibiotics can lead to the 
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development of cross-resistance to any of the other antibiotics 
of the same group (6). Common mechanisms of acquired 
resistance to MLSB antibiotics are modification of a target 
site by ribosomal RNA methylation, enzymatic inactivation 
and active efflux pump. Target site modification is mediated 
by the presence of erythromycin resistance methylase 
(erm) genes. Erythromycin resistance methylase (erm) 
genes encode methylases. Methylases cause conformational 
modification of 23S rRNA and lead to reduced binding 
of MLSB group of antibiotics to the target site in the 50S 
ribosomal subunit (7). Clindamycin is an alternative for 
penicillin allergic patients and 100% bioavailable when given 
orally. It has many advantages like low cost, fewer severe 
side effects, lack of need for renal adjustments, good tissue 
penetration and ability to directly inhibit toxin production 
(3, 5). In treatment of MRSA infections empirical use of 
clindamycin is common. However, routine in vitro testing 
for clindamycin susceptibility sometimes fails to detect 
inducible clindamycin resistance, leading to treatment failure 
(8, 9). For this reason detecting of inducible clindamiycin 
resistance is important. Clinical and Laboratory Standards 
Institute (CLSI) recommends the D zone test (disk diffusion 
test) or the broth microdilution test using a combination of 
erythromycin and clindamycin for strains of S. aureus that 
are resistant to erythromycin, but susceptible or intermediate 
to clindamycin, to detect inducible clindamycin resistance 
(10).
MATERIAL and METHODS
This study was conducted for a period from April 2013 to 
January 2015. Eighty six methicillin resistant S. aureus 
from various clinical samples (52 wound, 16 blood culture, 
9 tracheal aspirate, 7 urine, 1 cerebrospinal fluid and 1 ear 
discharge) from Microbiology Laboratory of Research 
Hospital of Ataturk University were included in this study. 
Duplicate isolates from the same patient were excluded. 
Isolates were identified by conventional methods and Vitek 
2 (BioMérieux, France) automated system. Antibiotic 
susceptibility tests were done by Kirby Bauer disc diffusion 
method on Mueller–Hinton agar plates using erythromycin, 
clindamycin, ciprofloxacin, levofloxacin, trimethoprim/
sulphametoxazole, linezolid, gentamicin, amikacin and 
tetracycline discs, methicillin resistance of the isolates were 
detected by disc diffusion method with 30 μg cefoxitin disc 
(Oxoid) and inducible clindamiycin resistance was detected 
by the D zone test according to Clinical and Laboratory 
Standards Institute (CLSI) recommends (10). S. aureus 
ATCC 43300 was used as quality control strain.
For the D zone test 2 μg clindamycin disc was placed at a 
distance of approximately 15 mm from 15 μg erythromycin 
disc on Mueller–Hinton agar plates previously inoculated 
with 0.5 McFarland bacterial suspensions. After the 
incubation (18-24 h. at 37 oC.) the diameter of ≤ 13 mm zone 
of inhibition for erythromycin, ≥ 21 mm for clindamycin 
and if the flattening of clindamycin zone on the side facing 
to erythromycin was considered as inducible clindamycin 
resistance positive (D zone test positive, iMLSB phenotype). 
If the isolate was erythromycin resistant and clindamycin 
susceptible and the zone of inhibition showing a circular 
shape, the isolate was considered to be negative for 
inducible resistance and the resistance was considered to 
be due to efflux pump (MS phenotype). Clindamycin and 
erythromycin resistant isolates were considered to have 
constitutive resistance (cMLSB phenotype) (11).
RESULTS
Antibiotic susceptibility results of our study showed that 
the most effective antibiotic was linezolid (100%) and the 
least effective was gentamicin (25.6%). Table 1 shows the 
susceptibility results of various antibiotics against MRSA 
strains.
According to the test results twenty of the strains exhibited 
the iMLSB, 8 exhibited the cMLSB and 22 exhibited the MS 
phenotype.
Table 1. Susceptibility results of various antibiotics against 
MRSA strains.
Antibiotics Susceptible
n (%)
Resistant
n (%)
Ciprofloxacin 23 (26.7) 63 (73.3)
Levofloxacin 36 (41.9) 50 (58.1)
Trimethoprim/sulphametoxazole 77 (89.5) 9 (10.5)
Linezolid 86 (100.0) 0 (0)
Gentamicin 22 (25.6) 64 (74.4)
Amikacin 49 (57.0) 37 (43.0)
Tetracycline 40 (46.5) 46 (53.5)
Erythromycin 36 (41.9) 50 (58.1)
Clindamycin 58 (67.4) 28 (32.6)
20 (23.25%) iMLSB
8 (9.30%) cMLSB
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DISCUSSION
Growing multidrug resistance in microorganisms causes 
serious problems of management and increases the need 
for new antibiotics. In addition to the cost of treatment, 
infections caused by resistant microorganisms are increasing 
morbidity and mortality (12). In our study the susceptibilities 
of MRSA strains to various antibiotics are investigated by disc 
diffusion method. As a result, linezolid was the most effective 
antibiotic (100%) and gentamicin was the least effective one 
(25.6%). Our findings were consistent with other studies on 
this aspect (13-15).
Resistance to macrolide, lincosamide and streptogramin 
B antibiotics results from acquisition of erm gene (16). 
MLSB resistance can occur as phenotypically, inductable 
or structural resistance. Clindamycin, a member of MLSB 
antibiotics is an appropriate choice for skin and soft tissue 
infections. Clindamycin resistance can be structural or 
inducible. Structural clindamycin resistance can be an easily 
recognizable case for both erythromycin and clindamycin 
resistance. Inducible resistance occurs in the presence 
of a strong inducer methylase ,such as, erythromycin or 
azithromycin and it can not be determined by standard test 
methods without D zone test (17, 18).
The incidence of MLSB phenotypes varies by geographical 
regions (19). According to results of a multicenter study 
conducted in Japan, the incidence of clindamycin resistance, 
including constitutive and inducible resistance, was 
approximately 26.7% (451/1688) for methicillin sensitive 
Staphylococcus aureus (MSSA) and 73.8% (482/653) for MRSA. 
The overall incidence of inducible clindamycin resistance 
among erythromycin-resistant and clindamycin-susceptible/
intermediate isolates was 91%. This study demonstrated a 
high rate of inducible resistance against clindamycin in MSSA 
and MRSA isolates in a local population (8). Mokta et al. (19) 
found that in MRSA strains (from Sub Himalayan Region of 
India) there were 29.62% cMLSB phenotype, 28.39% iMLSB 
phenotype and 13.58% MS phenotype. Juyal et al. (20) (from 
Garhwal Hills of Uttarakhand, India) demonstrated iMLSB 
phenotype in 13.3% of MRSA. Sasirekha et al.(11) (from 
Bangalore, India) reported that cMLSB phenotype was 
5.22% and iMLSB phenotype was 0.65% in MRSA strains. In 
another study, among the 297 S. aureus isolates, D zone test 
was positive in 13.46% and negative in 32.65% of the isolates 
(MS phenotype). Constitutive MLSB phenotype was seen in 
24.91% of the isolates (21). Focas et al. (22) (from Greece) 
have reported 15% iMLSB and 47% cMLSB phenotype in 
MRSA strains between 2002-2004. Schreckenberger et al. 
(23) have conducted a study in two different hospitals in the 
same region and reported that the incidences of inducible 
clindamycin resistance were 7% and 12% for MRSA strains. 
In other studies, done abroad, it has also been reported 
different results (24, 25).
In studies, different results have also been reported from 
our country. Şamlıoğlu et al (6) from İzmir, Turkey found 
that cMLSB phenotype was 9%, iMLSB phenotype was 87% 
and MS phenotype was 4% in all staphylococcal strains. In a 
different study from Turkey in 404 S.aureus strains there were 
4.70% cMLSB phenotype, 27.47% iMLSB phenotype and 
1.23% MS phenotype (26). Dizbay et al. (18) demonsrated 
that in 65 MRSA strains there were 6.15% iMLSB phenotype, 
and 64.61% cMLSB phenotype. Tekin et al. (7) (from 
Diyarbakir) have reported 1.7% iMLSB phenotype and 
87% cMLSB phenotype in MRSA strains. In a study from 
Gaziantep, Eksi et al. (27) have reported that 6.9% iMLSB 
phenotype and 39.6% cMLSB phenotype in 101 MRSA 
strains. Kaskatepe and Yildiz (28) reported that in 79 MRSA 
strains the incidence of iMLSB, cMLSB and MS phenotypes 
were respectively 18.9%, 27.9%, 16.5%. Durmaz et al. (29) 
have conducted a study with 38 MRSA and 144 MSSA 
strains and they reported that MLSB resistance phenotype 
was found higher in MRSA strains compared to MSSA 
strains, and this was statistically significant. In our study 
20 (23.25%) out of total 86 MRSA isolates were D zone test 
positive (iMLSB phenotype). There were 8 (9.30%) strains 
with cMLSB phenotype and 22 (25.58%) strains with MS 
phenotype. According to these results inducible clindamycin 
resistance in our hospital is not low.
CONCLUSIONS
The limited treatment options for MRSA strains increaes the 
importance of the right antibiotic. As seen from the results 
of many studies, inducible clindamycin resistance may vary 
by country, region, hospital and service in the same hospital. 
Therefore, we recommend clinical laboratories to report in 
vitro inducible clindamycin resistance in S. aureus isolates. 
The D zone test, a simple and important method for detection 
of MLSB phenotype, prevents the misuse of clindamycin.
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ÖZET
Klindamisin, Staphylococcus aureus enfeksiyonlarının 
tedavisinde önemli alternatif antibiyotiklerden biridir. MRSA 
tedavisinde seçeneklerin sınırlı olması doğru antibiyotik 
seçiminin önemini artırmaktadır. Klindamisinin bu 
enfeksiyonlarda kullanılmasındaki en önemli sorun, tedavinin 
başarısızlığına sebep olabilen indüklenebilir klindamisin 
direncinin varlığıdır. Bu çalışmanın amacı Atatürk Üniversitesi 
Araştırma Hastanesi’nden izole edilen 86 MRSA suşunda 
indüklenebilir klindamisin direnci varlığının araştırılmasıdır. 
İndüklenebilir klindamisin direnci varlığı Clinical and 
Laboratory Standards Institute (CLSI) önerileri doğrultusunda 
D zon test yöntemi kullanılarak saptandı. Suşlardan 20’sinde 
iMLSB, 8’inde cMLSB ve 22’sinde MS fenotipi görüldü. D 
zon test MLSB fenotipinin saptanmasında eritromisin ve 
klindamisin antibiyotik disklerini kullanarak yapılabilen basit 
bir disk difüzyon testidir ve klinik laboratuvarlar tüm S. aureus 
izolatlarında indüklenebilir klindamisin direncini bildirmelidir.
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